Dec. 17th 2019 -- Abimmune BioPharma today announced that it has scheduled a company presentation at Biotech Showcase™ 2020 to be held January 13–15, during the most important week in healthcare at the Hilton San Francisco Union Square.
Flora Fang, MD., PhD, the company Founder and CEO will be presenting Abimmune BioPharma at Biotech Showcase as follows:
Date: Monday, January 13th 2020
Time: 9am (PST)
Room: Franciscan B (Ballroom Level)
Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA (United States)
Founded by a team of serial inventor/entrepreneurs, Abimmune is developing novel multi-targeting immuno-oncology protein drugs. Several tri-specific or tetra-specific candidates are currently in the making. All anchor at the tumor-presenting dendritic cells or the tumor-killing T cells with synergized effects. The lead candidate will reach IND-enablement within a year. To maximize the chance for success, Abimmune’s candidates are built upon the clinically validated molecular targets/pathways using Abimmune’s proprietary technology platforms that are comprised of the single-domain antibodies, the multi-valence and multi-domain engineering technology, the protein sequence de-immunization, and the lymphoid tissue targeted drug delivery. Besides serving the cancer patients, Abimmune also strives for delivering the best values for investors.
Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry's largest gatherings and busiest weeks.
“We are delighted that Abimmune BioPharma will be presenting at Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase is a prime occasion for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery.”